We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

44 hedge funds and large institutions have $4.74M invested in NeuBase Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

2% more funds holding

Funds holding: 43 → 44 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

55% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 11

65% less capital invested

Capital invested by funds: $13.4M → $4.74M (-$8.64M)

Holders
44
Holders Change
+1
Holders Change %
+2.33%
% of All Funds
0.76%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
5
Reduced
11
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CM
CM Management
Florida
+$66.2K
2
Renaissance Technologies
Renaissance Technologies
New York
+$39.9K
3
TSS
Two Sigma Securities
New York
+$26.5K
4
Citadel Advisors
Citadel Advisors
Florida
+$18.9K
5
Millennium Management
Millennium Management
New York
+$18.4K

Top Sellers

1
SCM
Sio Capital Management
New York
-$535K
2
ACM
AIGH Capital Management
Maryland
-$129K
3
Deutsche Bank
Deutsche Bank
Germany
-$105K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$39.6K
5
WVP
Worth Venture Partners
New Jersey
-$36.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$1.08M – – –
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$494K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$419K – – –
DCMIC
4
Decheng Capital Management III (Cayman)
Cayman Islands
$395K – – –
CMU
5
Carnegie Mellon University
Pennsylvania
$371K – – –
ACM
6
AIGH Capital Management
Maryland
$345K -$129K -7,778 -15%
PAMP
7
Polar Asset Management Partners
Ontario, Canada
$251K – – –
KAS
8
Kestra Advisory Services
Texas
$201K -$827 -50 -0.2%
JAMONY
9
Jacob Asset Management of New York
California
$186K – – –
CM
10
CM Management
Florida
$178K +$66.2K +4,000 +22%
PCM
11
Prelude Capital Management
New York
$123K – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$114K +$39.9K +2,412 +20%
SCM
13
Sio Capital Management
New York
$102K -$535K -32,350 -71%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$92K – – –
WVP
15
Worth Venture Partners
New Jersey
$84K -$36.8K -2,226 -17%
PCM
16
Perkins Capital Management
Minnesota
$39K +$13.7K +825 +20%
Goldman Sachs
17
Goldman Sachs
New York
$32K -$248 -15 -0.4%
WPW
18
Waldron Private Wealth
Pennsylvania
$31K – – –
BlackRock
19
BlackRock
New York
$29K -$1.72K -104 -3%
State Street
20
State Street
Massachusetts
$27K – – –
Northern Trust
21
Northern Trust
Illinois
$22K – – –
TAM
22
Tocqueville Asset Management
New York
$17K -$9.1K -550 -21%
DC
23
Davenport & Co
Virginia
$16K -$4.14K -250 -11%
TSS
24
Two Sigma Securities
New York
$13K +$26.5K +1,600 New
Charles Schwab
25
Charles Schwab
California
$12K – – –
1
2

NBSE Hedge Fund Activity: Q3 2022 in Review

44 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2022, worth a combined $4.74M — down 65% from $13.4M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new NBSE positions and 6 closed out — a net gain of 1 holder — while 5 added to existing stakes and 11 trimmed.

The largest buyer was CM Management, adding an estimated $66.2K. The largest seller was Sio Capital Management, cutting an estimated $535K.

  • 44 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2022, up from 43 in Q2 2022.
  • Funds reported $4.74M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2022, down 65% quarter-over-quarter.
  • 7 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2022 and 6 closed out, a net change of +1 holder.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2022 was CM Management, an estimated $66.2K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2022 was Sio Capital Management, an estimated $535K sold.

Based on aggregated 13F filings for Q3 2022.